🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Zongertinib has the mildest side effects of any drug—ever—in the Exon 20 Group, and our HER2 Warriors cannot praise it enough. So grateful to John Heymach for being international PI of the practice-changing zongertinib study. #DAVALung

The lung cancer community came together to honor Nuria..not just for her joyful dancing videos, but for what she embodied: life, light, and connection in the face of EGFR cancer. Each clip shared is a tribute to the joy she gave us. We will carry it forward. #cancer #memorial

An emerging 4th-gen, brain-penetrant EGFR TKI. Dr. Ani Balmanoukian from Cedars-Sinai spotlights encouraging updates on BDTX-1535 in 2L/3L NSCLC. #DAVALung #LungCancer

I glanced through the list & not a SINGLE case of rare thoracic cancers: NUT midline, SMARCA4-UT, NRG1 or NTRK positive NSCLC, PSC, or even LCNEC! We can do better, please consider sharing your experiences. Young Lung Cancer Initiative OncoAlert LungCancerRx 🫁💊 FDA Oncology Kate Sears

Teliso-V is now approved for c-met overexpression metastatic non-squam NSCLC based off LUMINOSITY trial. We 🗣️ this trial, testing, findings, and AEs w/ D. Ross Camidge Full 🗣️: ⭐️ oncbrothers.com/fda-telisoV ⭐️ Also on “Oncology Brothers” podcast #OncTwitter #MedTwitter #lcsm

Coming up Sunday, June 29 @ 7PM ET: Join ALKtALK w/ Dr. Stephen Liu to explore how metastasis is managed in ALK+ cancer—from treatment changes to next steps after progression. Zoom in to feel informed, empowered, and prepared. alkpositive.org/alktalk #ALKPositive #ALKtALK

Hey Look Ma (& Dad), I made it! Honored to co author this piece on the unique challenges of young lung cancer -diagnosis, fertility survivorship & more Grateful to Narjust Florez, MD, FASCO #FlorezLab & the amazing team across institutions who made it possible frontiersin.org/journals/oncol…

Our community mourns the loss of Chad, who lived with RET+ lung cancer for 2.5 years. He loved deeply, lifted others and faced every setback with courage. His passing is a heartbreaking reminder: we still have a long way to go. Chad deserved more time. #LungCancerAwareness

Excited to share that we have been awarded $23.7 million grant from ARPA-H ADAPT program to investigate mechanisms of resistance & new therapies for IO resistant NSCLC! Honored to be PI on this with our leader Dr. Ravi Salgia #AritroNath cityofhope.org/city-of-hope-a…

Oncogene Cancer Research (Oncogene Cancer Research) - What Does it Take to Truly Move the Dial for People Facing Lung Cancer Yvonne Diaz Gianluca Casali Cecilia Pompili MD PhD FACS oncodaily.com/blog/people-fa… #OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews

New U.S. FDA accelerated approval: Sunvozertinib for EGFR exon20ins NSCLC after platinum chemo ▫️n=85, WU-KONG1B ▫️ORR: 46% ▫️DoR: 11.1 mo ⚠️ Diarrhea, rash, ⬆️ CK OncoAlert Exon 20 Group, a multistakeholder organization #lcsm

"New kid on the block"! Accelerated approval for Sunvozertinib for EGFR Ex20ins-mutated NSCLC. An increasingly favorable therapeutic landscape ASCO IASLC International Society of Liquid Biopsy

People with #lungcancer & low BMI are more likely to develop brain metastases - a link not seen in other cancers. New open access study in Nature Communications, July 2025. Researchers suggest it’s driven by brain signalling changes, not just weight loss. 🔗

Analysis of MARIPOSA JTO & JTO CRR comparing 1L lazertinib and osimertinib in #EGFR NSCLC. PFS 18.5m with lazertinib vs 16.6m with osimertinib (HR 0.98), RR 83% vs 85%, DOR 16.6m vs 16.8m, OS HR 1.00 - similar tox (laz more rash, osi more diarrhea). jto.org/article/S1556-…

In Aug ’21, I was unwell, had 2 biopsies & waited weeks for answers. A liquid biopsy trial gave me an ALK+ #lungcancer diagnosis in 10 days. Now NHS England is rolling this out! 🎙️ Alastair Greystoke & I spoke w Roy Castle Lung Cancer Foundation on this & more: 👉 roycastle.org/our-support/po… #LCSM

SCLC transformation from EGFR+ NSCLC, outcomes & tx? ESMO Open: - 25pts: CT (n=12), CT+EGFR-TKI (n=5), CT+ICI (n=6), CT+ICI+TKI (n=1) - mPFS 2m; mOS 9m, similar across tx - mOS if transf >12m v <12m (31m vs 8m, p<0.001) Chiara CATANIA OncoAlert #LCSM esmoopen.com/article/S2059-…

Was a pleasure for Yvonne Diaz to co-host Roy Castle Lung Cancer Foundation’s Talk of Hope podcast w Rachel Avery & Prof Alastair Greystoke. Talked about the use of blood biopsies to diagnose lung cancer on the NHS plus everything from the realities of living w stage 4 LC to the hope. Link👇

We’re proud to donate £10,425 to The ICR to advance oncogene-driven lung cancer research, supporting the vital work of Dr Paul Huang Paul Huang Lab. This is just the start — stay tuned for more big research plans. 💙🔬 oncogeneresearch.org/icr-donation #LCSM

If you love someone with cancer .. watch this 💧🌈 #cancer #lungcancer #caregiver